SCHEMBL257115

SCHEMBL257115

CC/C=C/c1c(Cl)cccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
KMT2A Q03164 5/20 0.44
MEN1 O00255 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSP90AA1 P07900 1/20 0.44
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
TYMP P19971 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 4/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 5/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14416284 1.00 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL10322856 1.00 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL257070 0.86 KCNH2 (0.51) ALDH1A1KMT2ATDP1POLBHPGD
SCHEMBL14416464 0.86 KCNH2 (0.51) ALDH1A1KMT2ATDP1POLBHPGD
SCHEMBL20091021 0.82 HSD11B1 (0.38) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL3433707 0.79 HSP90AA1 (0.39) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL10322154 0.79 HSP90AA1 (0.39) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL27168526 0.79 HSP90AA1 (0.47) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL11086039 0.79 KMT2A (0.46) ALDH1A1KMT2AMEN1TDP1HSP90AA1
SCHEMBL11086036 0.79 KMT2A (0.46) ALDH1A1KMT2AMEN1TDP1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
EP-2968210-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY BIO PHARM SOLUTIONS CO LTD (KR) 2024-09-11 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
CN-111419830-B Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes 比皮艾思药物研发有限公司 2024-01-30 CN disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
CN-115996905-A Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases 生物药品解决方案有限公司 2023-04-21 CN disclosed
CN-109939092-B Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome 比皮艾思药物研发有限公司 2022-03-22 CN disclosed
CN-109071424-B Sulfamate derivative compound, preparation method and application thereof 生物药品解决方案有限公司 2022-01-14 CN disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012028578-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER CROPSCIENCE AG (DE) 2012-03-08 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME CPT1B, MYLK, PYGM ALDH1A1 3483/4885KMT2A 940/4885MEN1 3930/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT ALDH1A1 1826/4885KMT2A 1213/4885MEN1 4859/4885
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES CPS1, BCHE, ACHE ALDH1A1 2234/4885KMT2A 507/4885MEN1 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.